New Drug Applications. To Company’s Knowledge, there exist no pending abbreviated new drug applications or other applications filed by third parties with respect to any of the Products for which there is no generic equivalent product on the market, whereby any such third-party could reasonably be expected to obtain approval to make, have made, use, sell, offer for sale, import, distribute, commercialize and otherwise dispose of any of the Products in the Territory on or prior to the Closing Date.
Appears in 3 contracts
Samples: Counterpart Agreement (Reliant Pharmaceuticals, Inc.), Loan and Guaranty Agreement (Reliant Pharmaceuticals, Inc.), Loan and Guaranty Agreement (Reliant Pharmaceuticals, Inc.)
New Drug Applications. To Company’s Knowledge, except as set forth in Schedule 4.26, there exist no pending abbreviated new drug applications or other applications filed by third parties with respect to any of the Products for which there is no generic equivalent product on the market, whereby any such third-third party could reasonably be expected to obtain approval to make, have made, use, sell, offer for sale, import, distribute, commercialize and otherwise dispose of any of the Products in the Territory on or prior to the Closing Date.
Appears in 2 contracts
Samples: Credit and Guaranty Agreement (Reliant Pharmaceuticals, Inc.), Credit and Guaranty Agreement (Reliant Pharmaceuticals, Inc.)
New Drug Applications. To Company’s Knowledge, there exist no pending abbreviated new drug applications or other applications filed by third parties with respect to any of the Products for which there is no generic equivalent product on the market, whereby any such third-third party could reasonably be expected to obtain approval to make, have made, use, sell, offer for sale, import, distribute, commercialize and otherwise dispose of any of the Products in the Territory on or prior to the Closing Date.
Appears in 1 contract
Samples: Loan and Guaranty Agreement (Reliant Pharmaceuticals, Inc.)
